Literature DB >> 6325044

The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycaemia in normal subjects.

R W Prescott, P Kendall-Taylor, D R Weightman, M J Watson, W A Ratcliffe.   

Abstract

The role of serotonin in the prolactin, growth hormone, ACTH and cortisol responses to hypoglycaemia has been investigated in normal subjects using a selective serotonin (5HT2) receptor antagonist, ketanserin. Circulating concentrations of these hormones were measured after administration of insulin (0.1 units/kg body weight iv) to eight normal male subjects with and without simultaneous iv ketanserin (10 mg). Plasma glucose fell to less than 2.0 mmol/1 in all subjects and was unaffected by ketanserin. Ketanserin induced a 50% decrease in the serum prolactin response to hypoglycaemia, 45 and 60 min after administration of insulin (increase in serum prolactin at 60 min: 1145 +/- 295 mU/l without ketanserin; 558 +/- 176 mU/l with ketanserin, P less than 0.05). The peak ACTH response was reduced by 30% (95.3 +/- 33.6 ng/l without ketanserin; 60.0 +/- 22.9 ng/l with ketanserin, P less than 0.05) but the plasma cortisol response was not significantly altered. The serum growth hormone response was unaffected by serotonin blockade. These findings suggest that serotonin, probably acting through 5HT2 receptors, is involved in the stimulation of prolactin and ACTH release but not in the release of growth hormone, during insulin induced hypoglycaemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325044     DOI: 10.1111/j.1365-2265.1984.tb00068.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

3.  The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.

Authors:  M L Drent; H J Adèr; E A van der Veen
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

4.  Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.

Authors:  N Sonino; G A Fava; F Fallo; A Franceschetto; P Belluardo; M Boscaro
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

5.  Prolactin unresponsiveness to repeated sulpiride administration in man: recent findings.

Authors:  G P Bernini; M Gasperi; G Gravina; M S Vivaldi; C Del Corso; R Santoni; M Luisi; F Franchi
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

6.  Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans.

Authors:  D Tepavcević; Z Giljević; I Aganović; M Korsić; S Halimi; E Suchanek; T Jelić; B Kozić; V Plavsić
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

7.  Effect of an oral serotonin antagonist, ketanserin, on plasma ACTH concentrations in Nelson's syndrome.

Authors:  R W Prescott; W A Ratcliffe; P K Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-29

8.  Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.

Authors:  Felix Hasler; Ulrike Grimberg; Marco A Benz; Theo Huber; Franz X Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

9.  Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans.

Authors:  D Tepavcević; Z Giljević; M Korsić; S Halimi; E Suchanek; T Jelić; I Aganović; B Kozić; V Plavsić
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.